【摘要】 用放射免疫分析法对201例女性血清β₂微球蛋白（β₂-M）进行检测,其中卵巢癌组42例,良性卵巢肿瘤组72例和正常对照组87例.结果表明,卵巢癌组的血清β₂-M较后两组明显升高,有极显著性差异（P<0.0001）,但良性卵巢肿瘤组和正常对照组的差异不显著（P>0.05）.以正常对照组血清β₂-M（?+2s）3.2mg/L作为正常值的上限,结果良性卵巢肿瘤组和卵巢癌组分别有11%（8/72）和64%（27/42）的病人血清β₂-M升高.卵巢癌Ⅰ～Ⅳ期分别有4/9,3/5,10/15和3/3的病人血清β₂-M升高,表明随着病情进展血清β₂-M渐升高.提示血清β₂-M可反映卵巢癌瘤负荷,是对卵巢癌诊断和鉴别诊断有价值的指标之一.更多还原

【Abstract】 Serum β₂ - microglobulin （ β₂ - M ） was determined by radioimmunoassay in 201 wo -men, including 42 with ovarian carcinoma, 72 with benign ovarian tumor and 87 normal controls . The result showed that the level of β₂ - M was markedly elevated in the group with ovarian carcinoma （P<0. 0001） but there was no difference between the group with bengin ovarian tumor and the control group. With 3.2mg/L （?+2s） of the control group taken as the upper limit of the normal level, we found 11% （8/72） in the benign tumor group and 64% （27/42） in the carcinoma group were above that limit. We also found that serum β₂-M was raised in 4/9 of the patients in stage Ⅰ , 3/5 in stage Ⅱ , 10/15 in stage Ⅲ and 3/3 in stage Ⅳ, which showed that the β₂-M content increased as the tumor progressed. The above suggests that serum β₂-M may reflect the ovarian tumor load and is one of the valuable ovarian tumor markers in the disgnosis ane discrimination of ovarian carcinoma.更多还原